Recent Advancements in the B7/CD28 Immune Checkpoint Families: New Biology and Clinical Therapeutic Strategies

Overview

Journal Cell Mol Immunol

Date 2023 Apr 17

PMID 37069229

Authors

Marc C Pulanco

Anne T Madsen

Ankit Tanwar

Devin T Corrigan

Xingxing Zang

Affiliations

Soon will be listed here.

Abstract

The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.

Citing Articles

Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.

Jiang K, Wang S Transl Breast Cancer Res. 2025; 6:9.

PMID: 39980806 PMC: 11836745. DOI: 10.21037/tbcr-24-38.

PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.

Kantheti U, Forward T, Lucas E, Schafer J, Tamburini P, Burchill M Sci Adv. 2025; 11(5):eadt3044.

PMID: 39879305 PMC: 11777207. DOI: 10.1126/sciadv.adt3044.

Enhancing the Chemosensitivity of MKN-45 Gastric Cancer Cells to Docetaxel via Suppression: A Novel Therapeutic Strategy.

Aslan E, Akcali N, Yavas C, Eslamkhah S, Gur S, Batur L Life (Basel). 2025; 14(12.

PMID: 39768254 PMC: 11676808. DOI: 10.3390/life14121546.

B7-H3 in glioblastoma and beyond: significance and therapeutic strategies.

Babic D, Jovcevska I, Zottel A Front Immunol. 2024; 15():1495283.

PMID: 39664380 PMC: 11632391. DOI: 10.3389/fimmu.2024.1495283.

Immunoregulatory protein B7-H3 upregulated in bacterial and viral infection and its diagnostic potential in clinical settings.

Tigabu A Front Immunol. 2024; 15:1472626.

PMID: 39497833 PMC: 11532155. DOI: 10.3389/fimmu.2024.1472626.

References

Chen D, Chen W, Xu Y, Zhu M, Xiao Y, Shen Y . Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J Med Genet. 2018; 56(1):43-49. DOI: 10.1136/jmedgenet-2018-105454. View

Wei Y, Ren X, Galbo Jr P, Moerdler S, Wang H, Sica R . KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021; 6(61). PMC: 9744578. DOI: 10.1126/sciimmunol.abf9792. View

Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y . Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway. Oncogene. 2018; 37(30):4164-4180. DOI: 10.1038/s41388-018-0252-x. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Oh S, Kim S, Keam B, Kim T, Kim D, Heo D . Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021; 11(1):19712. PMC: 8492653. DOI: 10.1038/s41598-021-99311-y. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Jing C, Fu Y, Yi Y, Zhang M, Zheng S, Huang J . HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer. 2019; 7(1):77. PMC: 6421676. DOI: 10.1186/s40425-019-0554-8. View

Guzik K, Zak K, Grudnik P, Magiera K, Musielak B, Torner R . Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017; 60(13):5857-5867. DOI: 10.1021/acs.jmedchem.7b00293. View

Oestreich K, Yoon H, Ahmed R, Boss J . NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008; 181(7):4832-9. PMC: 2645436. DOI: 10.4049/jimmunol.181.7.4832. View

10.

Zhou S, Zhu J, Xu J, Gu B, Zhao Q, Luo C . Anti-tumour potential of PD-L1/PD-1 post-translational modifications. Immunology. 2022; 167(4):471-481. DOI: 10.1111/imm.13573. View

11.

Bastian K, Scott E, Elliott D, Munkley J . FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer. Int J Mol Sci. 2021; 22(1). PMC: 7795606. DOI: 10.3390/ijms22010455. View

12.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

13.

Tang X, Liu F, Liu Z, Cao Y, Zhang Z, Wang Y . Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma. Clin Transl Immunology. 2020; 9(6):e1137. PMC: 7292833. DOI: 10.1002/cti2.1137. View

14.

Wu J, Wang F, Liu X, Zhang T, Liu F, Ge X . Correlation of IDH1 and B7H3 expression with prognosis of CRC patients. Eur J Surg Oncol. 2018; 44(8):1254-1260. DOI: 10.1016/j.ejso.2018.05.005. View

15.

Zhao R, Chinai J, Buhl S, Scandiuzzi L, Ray A, Jeon H . HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A. 2013; 110(24):9879-84. PMC: 3683785. DOI: 10.1073/pnas.1303524110. View

16.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

17.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

18.

Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin Y . BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022; 7(76):eabk0957. DOI: 10.1126/sciimmunol.abk0957. View

19.

Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A . Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin Cancer Res. 2016; 22(23):5661-5672. DOI: 10.1158/1078-0432.CCR-15-3104. View

20.

Lim S, Wei J, Nguyen T, Shi H, Su W, Palacios G . Lipid signalling enforces functional specialization of T cells in tumours. Nature. 2021; 591(7849):306-311. PMC: 8168716. DOI: 10.1038/s41586-021-03235-6. View